Home
>
US Stocks
>
Angion Biomedica Corp
Angion Biomedica Corp
ANGN

Angion Biomedica Corp

$8.6512.18%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
8.55
Today Low/High
8.55 / 8.9
52 Week Low/High
$9.11 / $26.3
Market Cap
$282.19M

Company Details

Angion Biomedica Corp. is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation, a Phase 2 trial in cardiac-surgery associated acute kidney injury, and a Phase 2 trial in patients with COVID-19 related pneumonia at high risk for acute respiratory distress syndrome. Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
Organisation
Angion Biomedica Corp
Employees
53

Discover more

Frequently Asked Questions

What is Angion Biomedica Corp share price today

Can Indians buy Angion Biomedica Corp shares?

How can I buy Angion Biomedica Corp shares from India?

Can Fractional shares of Angion Biomedica Corp be purchased?

What are the documents required to start investing in Angion Biomedica Corp stocks?

We are a SEBI registered investement advisor